TABLE 1:
Univariate and Multivariable Model predicting decline in eGFR ≤45 among patients with preoperative eGFR ≥60
| Clinical Variable (n = 668) | Univariate Model |
Final Multivariable Model |
||||
|---|---|---|---|---|---|---|
| Hazard Ratio (HR) | 95% HR Confidence Limits | p-value | Hazard Ratio (HR) | 95% HR Confidence Limits | p-value | |
| Age | Linear Term | Spline Coefficient 11.07 | ||||
| Median 61 yrs (IQR 52–69 yrs) | Only 1.05 | 1.03–1.06 | <0.001 | 1.03–1.12 | 0.001* | |
| Spline Coefficient 20.99 | 0.95–1.03 | 0.6* | ||||
| Tumor size | Linear Term | Spline Coefficient 11.02 | ||||
| Median 6 cm (IQR 4–9.5 cm) | Only 0.97 | 0.93–1.02 | 0.2 | 0.89–1.18 | 0.8* | |
| Spline Coefficient 20.95 | 0.77–1.16 | 0.6* | ||||
| Race | Tab | |||||
| Non-Black (n=611; 91%) | Ref | Ref | ||||
| Black (n=57; 9%) | 1.62 | 0.92–2.85 | 0.097 | 0.95 | 0.48–1.89 | 0.9 |
| Gender | ||||||
| Male (n=430; 64%) | Ref | Ref | ||||
| Female (n=238; 36%) | 1.06 | 0.74–1.51 | 0.7 | 5.58 | 3.20–9.75 | <0.001 |
| Cardiac Disease | ||||||
| No (n=556; 83%) | Ref | Ref | ||||
| Yes (n=112; 17%) | 1.68 | 1.10–2.59 | 0.017 | 1.05 | 0.63–1.75 | 0.9 |
| Hypertension | ||||||
| No (n=295; 44%) | Ref | Ref | ||||
| Yes (n=373; 56%) | 1.54 | 1.08–2.18 | 0.016 | 0.93 | 0.62–1.41 | 0.7 |
| Peripheral Vascular Disease | ||||||
| No (n=659; 99%) | Ref | Ref | ||||
| Yes (n=9; 1%) | 5.45 | 1.35–22.0 | 0.017 | 4.89 | 1.06–22.59 | 0.042 |
| Diabetes | ||||||
| No (n=563; 84%) | Ref | Ref | ||||
| Yes (n=105; 16%) | 1.40 | 0.90–2.19 | 0.14 | 1.24 | 0.72–2.13 | 0.4 |
| Pre-operative Creatinine | Spline Coefficient 11902 | |||||
| Median 0.9 mg/dL (IQR 0.8–1.05) | Linear term 38.7 | 14.1–106.4 | <0.001 | 127–28,596 | <0.001 * | |
| Spline Coefficient 20.19 | 0.0009–37.5 | 0.6* | ||||
*
p-values for joint tests that both spline coefficients are equal to zero: Age p<0.001, Size p=0.8, Pre-operative Creatinine p<0.001
IQR=Interquartile Range